Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis

Published:2022-10-19 Issue:12 Volume:36 Page:2817-2826
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Short Nicholas J.^ORCID,Fu Chenqi,Berry Donald A.,Walter Roland B.^ORCID,Freeman Sylvie D.^ORCID,Hourigan Christopher S.,Huang Xuelin,Gonzalez Graciela Nogueras^ORCID,Hwang Hyunsoo,Qi Xinyue,Kantarjian Hagop^ORCID,Zhou Shouhao^ORCID,Ravandi Farhad^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-022-01692-0.pdf

Reference66 articles.

1. Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392:593–606.

2. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

3. Walter RB, Kantarjian HM, Huang X, Pierce SA, Sun Z, Gundacker HM, et al. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. J Clin Oncol: Off J Am Soc Clin Oncol. 2010;28:1766–71.

4. Chen X, Xie H, Wood BL, Walter RB, Pagel JM, Becker PS, et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J Clin Oncol: Off J Am Soc Clin Oncol. 2015;33:1258–64.

5. Short NJ, Rafei H, Daver N, Hwang H, Ning J, Jorgensen JL, et al. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. Blood Adv. 2020;4:6117–26.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurable residual disease in haematological and solid cancers;Leukemia;2024-06-27

2. Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients;Cancer Reports;2024-04

3. Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions;Biomedicines;2024-03-07

4. Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts;International Journal of Molecular Sciences;2024-02-10

5. Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide;Bone Marrow Transplantation;2024-01-05